Is Atreca Inc (BCEL) Stock About to Get Hot Friday?

The market has been high on Atreca Inc (BCEL) stock recently. BCEL gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Atreca Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BCEL!

See Full BCEL Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With BCEL Stock Today?

Atreca Inc (BCEL) stock is unchanged 0% while the S&P 500 is lower by -0.33% as of 11:49 AM on Friday, May 19. BCEL is unmoved $0.00 from the previous closing price of $1.10 on volume of 50,076 shares. Over the past year the S&P 500 is higher by 6.64% while BCEL is lower by -37.14%. BCEL lost -$2.40 per share in the over the last 12 months.

More About Atreca Inc

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. Click Here to get the full Stock Report for Atreca Inc stock.